Search
Plus Therapeutics Inc
PSTVAdd to Watchlist
4.160USD
-0.210-4.81%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
23.08MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-4.81%
5 Days
+1.96%
1 Month
-28.52%
6 Months
-67.52%
Year to Date
-67.52%
1 Year
-52.16%
Key Figures
4.390Open
4.510High
139.00KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.77%Turnover Ratio
4.370Prev. Close
4.150Low
473.44KTurnover
LossP/E Static
8.56P/B
0.00%Div Yield TTM
-195.02%ROA
23.42552wk High
0.81Volume Ratio
-12.98MNet Profit
5.55MShares
-7.1930EPS TTM
1.40Beta
-522.50%ROE
2.90052wk Low
8.07%Amplitude
100.00%Gross Margin
23.08MMarket Cap
0.57Reward/Risk
7.23%Risk Rate
TradingKey Stock Score of Plus Therapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Plus Therapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 134 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 36.00.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Plus Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Plus Therapeutics Inc Highlights
StrengthsRisks
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.21M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.21M.
Undervalued
The company’s latest PE is -1.26, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.08M shares, increasing 43.32% quarter-over-quarter.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
36.000
Target Price
+723.80%
Upside Space
Plus Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Plus Therapeutics Inc Info
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Ticker SymbolPSTV
CompanyPlus Therapeutics Inc
CEOHedrick (Marc H)
Websitehttp://www.plustherapeutics.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Plus Therapeutics Inc (PSTV)?
The current price of Plus Therapeutics Inc (PSTV) is 4.37.
What is the symbol of Plus Therapeutics Inc?
The ticker symbol of Plus Therapeutics Inc is PSTV.
What is the 52-week high of Plus Therapeutics Inc?
The 52-week high of Plus Therapeutics Inc is 23.43.
What is the 52-week low of Plus Therapeutics Inc?
The 52-week low of Plus Therapeutics Inc is 2.90.
What is the market capitalization of Plus Therapeutics Inc?
The market capitalization of Plus Therapeutics Inc is 30.08M.
Is Plus Therapeutics Inc (PSTV) currently rated as Buy, Hold, or Sell?
According to analysts, Plus Therapeutics Inc (PSTV) has an overall rating of Buy, with a price target of 36.00.
What is the Earnings Per Share (EPS TTM) of Plus Therapeutics Inc (PSTV)?
The Earnings Per Share (EPS TTM) of Plus Therapeutics Inc (PSTV) is -7.19.